| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 16,9 M € | -5.3% | 17,9 M € | +11.9% | 16,0 M € | — | — | — | — | — | — | — | 8,8 M € | +25.0% | 7,0 M € | +14.3% | 6,1 M € | -0.3% | 6,2 M € | +17.1% | 5,3 M € | — | — | — | — | — | ||||||||||||||
| Gross margin | — | — | — | 1,2 M € | -1.0% | 1,2 M € | +14.1% | 1,1 M € | -11.5% | 1,2 M € | +11.3% | 1,1 M € | +11.0% | 984,3 k € | +9.5% | 898,9 k € | — | — | — | — | — | 514,7 k € | +32.1% | 389,5 k € | -16.1% | 464,1 k € | +25.4% | 370,2 k € | +13.0% | 327,6 k € | ||||||||||
| EBITDA | 798,0 k € | -15.9% | 949,3 k € | +51.1% | 628,3 k € | -28.2% | 875,3 k € | -6.9% | 940,6 k € | +18.1% | 796,5 k € | -15.3% | 940,7 k € | +53.2% | 614,1 k € | -20.6% | 773,1 k € | +12.0% | 690,4 k € | +14.8% | 601,3 k € | +31.0% | 458,8 k € | -0.6% | 461,7 k € | -0.6% | 464,3 k € | +8.3% | 428,7 k € | +0.0% | 428,7 k € | +38.2% | 310,1 k € | -19.5% | 385,3 k € | +32.0% | 291,9 k € | +13.2% | 257,8 k € | |
| Operating profit | 775,1 k € | -15.2% | 914,4 k € | +51.5% | 603,4 k € | -29.1% | 850,6 k € | -6.8% | 912,4 k € | +20.1% | 759,8 k € | -16.5% | 909,5 k € | +55.6% | 584,4 k € | -20.3% | 733,0 k € | +12.5% | 651,3 k € | +14.3% | 569,8 k € | +32.6% | 429,6 k € | -3.9% | 447,0 k € | +0.0% | 447,0 k € | +8.7% | 411,2 k € | +0.2% | 410,3 k € | +40.5% | 292,0 k € | -20.7% | 368,2 k € | +32.3% | 278,3 k € | +14.0% | 244,2 k € | |
| Profit/loss | 561,9 k € | -18.0% | 684,9 k € | +55.4% | 440,8 k € | -34.8% | 676,1 k € | -3.4% | 699,9 k € | +25.1% | 559,5 k € | -13.8% | 649,1 k € | +44.3% | 449,7 k € | -2.2% | 459,7 k € | +2.4% | 448,8 k € | +12.5% | 399,1 k € | +26.0% | 316,9 k € | +2.2% | 310,1 k € | -14.5% | 362,8 k € | +18.3% | 306,7 k € | +0.2% | 306,0 k € | +33.7% | 228,9 k € | -21.5% | 291,6 k € | +33.2% | 218,8 k € | +15.0% | 190,3 k € | |
| Equity | 4,0 M € | +16.6% | 3,4 M € | -0.4% | 3,4 M € | +4.3% | 3,3 M € | +26.1% | 2,6 M € | -7.2% | 2,8 M € | -13.6% | 3,2 M € | +4.8% | 3,1 M € | +17.1% | 2,6 M € | -1.5% | 2,7 M € | -17.1% | 3,2 M € | +14.1% | 2,8 M € | +12.7% | 2,5 M € | +14.1% | 2,2 M € | +19.8% | 1,8 M € | +20.1% | 1,5 M € | -13.9% | 1,8 M € | +14.8% | 1,5 M € | +23.3% | 1,3 M € | +21.2% | 1,0 M € | |
| Total assets | 5,9 M € | -10.2% | 6,6 M € | +13.0% | 5,8 M € | -7.3% | 6,3 M € | +29.8% | 4,8 M € | +27.3% | 3,8 M € | -24.5% | 5,0 M € | +36.8% | 3,7 M € | -8.3% | 4,0 M € | +4.5% | 3,8 M € | -17.7% | 4,6 M € | -12.4% | 5,3 M € | +82.4% | 2,9 M € | +16.4% | 2,5 M € | +24.6% | 2,0 M € | -3.9% | 2,1 M € | -2.7% | 2,1 M € | +20.2% | 1,8 M € | +22.1% | 1,5 M € | +8.6% | 1,3 M € | |
| Cash | 1,6 M € | +71.1% | 945,0 k € | -18.2% | 1,2 M € | +63.6% | 705,9 k € | -58.7% | 1,7 M € | +161.1% | 654,5 k € | +97.8% | 330,9 k € | -50.5% | 668,1 k € | +29.8% | 514,7 k € | -3.9% | 535,5 k € | +52.1% | 352,1 k € | -21.2% | 446,7 k € | +60.8% | 277,9 k € | -75.3% | 1,1 M € | +56.0% | 720,8 k € | -10.3% | 803,7 k € | +298.9% | 201,5 k € | +82.4% | 110,5 k € | -37.1% | 175,7 k € | +7.9% | 162,8 k € | |
| Debts | 1,8 M € | -42.7% | 3,1 M € | +38.2% | 2,2 M € | -17.7% | 2,7 M € | +33.0% | 2,0 M € | +140.7% | 847,9 k € | -50.8% | 1,7 M € | +198.8% | 576,6 k € | -52.0% | 1,2 M € | +10.9% | 1,1 M € | -23.0% | 1,4 M € | -38.6% | 2,3 M € | +473.7% | 399,4 k € | +33.2% | 299,9 k € | +74.2% | 172,2 k € | -68.8% | 551,4 k € | +51.5% | 364,1 k € | +63.7% | 222,4 k € | +27.8% | 173,9 k € | -35.7% | 270,5 k € | |
| Staff | 5,8 | 6 | 6 | 5,6 | 5 | 5 | 5 | 5 | 4 | 4 | 4,3 | 4 | 3,3 | 2,4 | 2 | 2 | 2 | 2 | 2 | 2,1 | ||||||||||||||||||||
Public limited company · Schaerbeek · incorporated on 27/10/1992 · 5,8 ETP
Public limited company profitable and well capitalised. Cash position rising (+71.1%).
Solid counterparty for a standard engagement.
IBIS PHARMA is a Public limited company incorporated in 1992. Its main activity is: Wholesale of pharmaceutical goods. Its registered office is in Schaerbeek. It employs on average 5,8 ETP workers (FTE).
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette